261 related articles for article (PubMed ID: 27982602)
1. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin.
Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X
Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602
[TBL] [Abstract][Full Text] [Related]
2. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
3. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy.
Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y
Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317
[TBL] [Abstract][Full Text] [Related]
4. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
5. Lysosome-Independent Intracellular Drug/Gene Codelivery by Lipoprotein-Derived Nanovector for Synergistic Apoptosis-Inducing Cancer-Targeted Therapy.
Wang W; Chen K; Su Y; Zhang J; Li M; Zhou J
Biomacromolecules; 2018 Feb; 19(2):438-448. PubMed ID: 29334216
[TBL] [Abstract][Full Text] [Related]
6. Construction of a biodegradable, versatile nanocarrier for optional combination cancer therapy.
Wen J; Lv Y; Xu Y; Zhang P; Li H; Chen X; Li X; Zhang L; Liu F; Zeng W; Sun S
Acta Biomater; 2019 Jan; 83():359-371. PubMed ID: 30414486
[TBL] [Abstract][Full Text] [Related]
7. Coloaded Nanoparticles of Paclitaxel and Piperlongumine for Enhancing Synergistic Antitumor Activities and Reducing Toxicity.
Liu Q; Zhao D; Zhu X; Chen H; Yang Y; Xu J; Zhang Q; Fan A; Li N; Guo C; Kong Y; Lu Y; Chen X
J Pharm Sci; 2017 Oct; 106(10):3066-3075. PubMed ID: 28552690
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
[TBL] [Abstract][Full Text] [Related]
9. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L
Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436
[TBL] [Abstract][Full Text] [Related]
10. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier.
Yuan Y; Wang W; Wang B; Zhu H; Zhang B; Feng M
J Drug Target; 2013 May; 21(4):367-74. PubMed ID: 23600747
[TBL] [Abstract][Full Text] [Related]
11. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
Lv S; Tang Z; Li M; Lin J; Song W; Liu H; Huang Y; Zhang Y; Chen X
Biomaterials; 2014 Jul; 35(23):6118-29. PubMed ID: 24794923
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effect of folate-targeted Pluronic™ F-127/poly(lactic acid) polymersomes for codelivery of doxorubicin and paclitaxel.
Wu TY; Li ZL; Gong YC; Xiong XY
Nanomedicine (Lond); 2023 Feb; 18(5):455-469. PubMed ID: 37166001
[TBL] [Abstract][Full Text] [Related]
14. Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells.
Wu C; Xu J; Hao Y; Zhao Y; Qiu Y; Jiang J; Yu T; Ji P; Liu Y
Int J Nanomedicine; 2017; 12():7979-7992. PubMed ID: 29184399
[TBL] [Abstract][Full Text] [Related]
15. A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles.
Wang Y; Ma S; Xie Z; Zhang H
Colloids Surf B Biointerfaces; 2014 Apr; 116():41-8. PubMed ID: 24441457
[TBL] [Abstract][Full Text] [Related]
16. Dual-functional bio-derived nanoparticulates for apoptotic antitumor therapy.
Ding Y; Wang Y; Opoku-Damoah Y; Wang C; Shen L; Yin L; Zhou J
Biomaterials; 2015 Dec; 72():90-103. PubMed ID: 26344366
[TBL] [Abstract][Full Text] [Related]
17. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers.
Yi X; Lian X; Dong J; Wan Z; Xia C; Song X; Fu Y; Gong T; Zhang Z
Mol Pharm; 2015 Nov; 12(11):4085-98. PubMed ID: 26422373
[TBL] [Abstract][Full Text] [Related]
20. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]